- Home
- ADIL vs INBS Comparison
ADIL vs INBS Comparison
Compare ADIL & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | INBS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.4M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ADIL | INBS |
|---|---|---|
| Price | $1.89 | $3.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 82.7K |
| Earning Date | 03-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.54 |
| 52 Week High | $3.67 | $24.90 |
Technical Indicators
Market Signals| Indicator | ADIL | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 29.93 |
| Support Level | $0.28 | $1.49 |
| Resistance Level | $3.67 | $7.25 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 45.95 | 13.93 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.